The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Open accessAbstract
Management of prosthetic vascular graft infections caused by Pseudomonas aeruginosa can be a significant challenge to clinicians. These infections often do not resolve with antibiotic therapy alone due to antibiotic resistance/tolerance by bacteria, poor ability of antibiotics to permeate/reduce biofilms and/or other factors. Bacteriophage OMKO1 binding to efflux pump proteins in P. aeruginosa was consistent with an evolutionary trade-off: wildtype bacteria were killed by phage whereas evolution of phage-resistance led to increased antibiotic sensitivity. However, phage clinical-use has not been demonstrated. Here, we present a case report detailing therapeutic application of phage OMKO1 to treat a chronic P. aeruginosa infection of an aortic Dacron graft with associated aorto-cutaneous fistula. Following a single application of phage OMKO1 and ceftazidime, the infection appeared to resolve with no signs of recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance of bacteria in biofilms
Stewart, P. S., & William Costerton, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05321-1 · Cited by 4,585
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Targeting virulence: a new paradigm for antimicrobial therapy
Clatworthy, A. E., Pierson, E., & Hung, D. T. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.24 · Cited by 1,406
Aminoglycoside antibiotics induce bacterial biofilm formation
Hoffman, L. R., D'Argenio, D. A., MacCoss, M. J., Zhang, Z., Jones, R. A., & Miller, S. I. (2005) · Nature · doi:10.1038/nature03912 · Cited by 1,321
An overview of nosocomial infections, including the role of the microbiology laboratory
Emori, T. G., & Gaynes, R. P. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.428 · Cited by 1,286
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Wright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E. (2016) · Scientific Reports · doi:10.1038/srep26717 · Cited by 715
Self-citationTargeting virulence: can we make evolution-proof drugs?
Allen, R. C., Popat, R., Diggle, S. P., & Brown, S. P. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3232 · Cited by 532
Cited by
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0437-z · Cited by 1,410
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kortright, K. E., Chan, B. K., Koff, J. L., & Turner, P. E. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.014 · Cited by 1,212
Self-citationPhage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
Uyttebroek, S., Chen, B., Onsea, J., Ruythooren, F., Debaveye, Y., Devolder, D., Spriet, I., Depypere, M., Wagemans, J., Lavigne, R., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00612-5 · Cited by 411
Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac453 · Cited by 344
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Mechanisms and clinical importance of bacteriophage resistance
Egido, J. E., Costa, A. R., Aparicio-Maldonado, C., Haas, P.-J., & Brouns, S. J. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab048 · Cited by 325
Eskenazi, A., Lood, C., Wubbolts, J., Hites, M., Balarjishvili, N., Leshkasheli, L., Askilashvili, L., Kvachadze, L., van Noort, V., Wagemans, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27656-z · Cited by 287
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
Aslam, S., Courtwright, A. M., Koval, C., Lehman, S. M., Morales, S., Furr, C.-L. L., Rosas, F., Brownstein, M. J., Fackler, J. R., Sisson, B. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15503 · Cited by 285
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies
Liu, D., Van Belleghem, J. D., de Vries, C. R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J. R., Amanatullah, D. F., Tamma, P. D., & Suh, G. A. (2021) · Viruses · doi:10.3390/v13071268 · Cited by 268
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong, T., Salabarria, A.-C., & Roach, D. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.014 · Cited by 266
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
The genetic basis of phage susceptibility, cross-resistance and host-range in Salmonella
Adler, B. A., Kazakov, A. E., Zhong, C., Liu, H., Kutter, E., Lui, L. M., Nielsen, T. N., Carion, H., Deutschbauer, A. M., Mutalik, V. K., et al. (2021) · Microbiology · doi:10.1099/mic.0.001126 · Cited by 65
Interaction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy
Jariah, R. O. A., & Hakim, M. S. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2055 · Cited by 40
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Metadata
- Authors
- Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D.
- Venue
- Evolution, Medicine, and Public Health
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-01
- Volume
- 2018
- Issue
- 1
- Pages
- 60-66
- ISSN
- 2050-6201 (ISSN-L)
- OpenAlex
- W2793264270
- Cited by
- 501
- References
- 27
- FWCI
- 36.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.